BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Clinical Trials
1.7k
Trial Phases
6 Phases
Drug Approvals
11
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1339 trials with phase data)• Click on a phase to view related trials
A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT07215975
- Locations
- 🇸🇦
Prince Muhammad bin Nasser Hospital, Jizan, Saudi Arabia
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Biological: Nivolumab + ipilimumab + platinum-based chemotherapyBiological: Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapyBiological: Other dual-immuno-oncology therapy with chemotherapy
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 300
- Registration Number
- NCT07215962
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Fleming Island, Florida, United States
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Conditions
- Renal Cell Carcinoma
- Interventions
- Drug: BMS-986506
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 125
- Registration Number
- NCT07195682
- Locations
- 🇺🇸
Local Institution - 0029, New York, New York, United States
🇺🇸Local Institution - 0006, Boston, Massachusetts, United States
🇺🇸Local Institution - 0002, Philadelphia, Pennsylvania, United States
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: Current standard of care treatment options
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 223
- Registration Number
- NCT07175285
- Locations
- 🇺🇸
Local Institution - 0035, San Diego, California, United States
🇺🇸Local Institution - 0034, Ann Arbor, Michigan, United States
🇺🇸Local Institution - 0039, Brooklyn, New York, United States
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Placebo
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT07171983
- Prev
- 1
- 2
- 3
- 4
- 5
- 300
- Next
News
Takeda Expands AI Drug Discovery Partnership with Nabla Bio in $1B+ Deal
Takeda Pharmaceutical has signed a second multi-year AI partnership with Nabla Bio, potentially worth over $1 billion including milestone payments, to accelerate early-stage drug discovery using artificial intelligence.
iMDx Appoints Marketing VP to Spearhead Commercial Launch of Transplant Rejection Diagnostic
Insight Molecular Diagnostics (iMDx) has appointed Steven Tahmooressi as Vice President of Marketing to lead the commercial launch of its GraftAssureDx transplant rejection diagnostic kit.
Bristol Myers Squibb and Lilly Showcase Major Oncology Data at ESMO 2025
Bristol Myers Squibb will present data from over 50 studies at ESMO 2025, including first-in-class results from izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific ADC that received FDA Breakthrough Therapy designation for EGFR-mutated NSCLC.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.
Bristol Myers Squibb Acquires Orbital Therapeutics for $1.5 Billion to Advance In Vivo CAR-T Cell Therapy
Bristol Myers Squibb announced the acquisition of private startup Orbital Therapeutics for $1.5 billion in cash to strengthen its cell therapy portfolio.
Halozyme Acquires Elektrofi for $750M to Expand Ultra-High Concentration Drug Delivery Technology
Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.
Bristol Myers Squibb's Anti-Tau Antibody BMS-986446 Receives FDA Fast Track Designation for Alzheimer's Disease
The FDA has granted Fast Track Designation to BMS-986446, Bristol Myers Squibb's anti-microtubule binding region-tau antibody currently in Phase 2 development for early Alzheimer's disease.
Major Pharma Companies Form AI Consortium to Accelerate Drug Discovery Through Federated Data Sharing
Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals are joining an AI consortium with AbbVie and Johnson & Johnson to train the OpenFold3 drug discovery model.
FDA Halts New Drug Application Acceptance as Government Shutdown Begins
The FDA will not accept new drug applications during the government shutdown, though it can continue reviewing existing submissions funded by user fees.
Revolution Medicines Appoints Alan Sandler as Chief Development Officer to Advance RAS-Targeted Cancer Pipeline
Revolution Medicines has appointed Alan Sandler, M.D. as chief development officer to lead development of RAS(ON) inhibitors for RAS-addicted cancers.